| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
17 |
| Employees |
180 |
| Revenues (TTM) (Millions $) |
38 |
| Net Income (TTM) (Millions $) |
-30 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Avedro Inc is a medical technology company that specializes in the development and commercialization of devices and systems for treating corneal diseases and disorders. The company was founded in 2002 and is headquartered in Waltham, Massachusetts, with additional offices in Germany and Italy.
Avedro focuses on developing products that use corneal cross-linking technology, which involves the use of ultraviolet light and special riboflavin solutions to strengthen the cornea. This technology has been proven effective in treating keratoconus, a progressive eye disease that causes the cornea to thin and bulge, as well as other corneal disorders.
One of Avedro's main products is the KXLe System, which is used to perform corneal cross-linking procedures. The KXLe system is an advanced device that delivers precise doses of UV light to the cornea, while monitoring the treatment in real-time to ensure safety and efficacy. The system has been approved by the US FDA and is used by ophthalmologists and eye surgeons worldwide.
Avedro also produces other corneal cross-linking devices and solutions, including the Photrexae Viscous, Photrexae and the Mosaice System. These products are used in different stages of the corneal cross-linking procedure to deliver precise treatments that are tailored to the patient's unique needs.
In addition to its products, Avedro has an extensive network of clinical and research partnerships with leading ophthalmologists and eye institutes around the world. The company is committed to advancing the field of corneal cross-linking through continued research and development, and is focused on developing new treatments and solutions to improve the lives of patients with corneal disorders.
Overall, Avedro Inc is a pioneering company that is at the forefront of developing innovative technologies and treatments for corneal disorders. The company's products and solutions have already made a significant impact in the field of ophthalmology, and are expected to continue improving the lives of patients with corneal conditions for years to come.
Company Address: 201 Jones Road Waltham 2451 MA
Company Phone Number: 768-3400 Stock Exchange / Ticker: NASDAQ AVDR
|
%